Date: 2014-03-31
Type of information: R&D agreement
Compound: compounds against a novel GPCR pain target
Company: Evotec (Germany) Convergence Pharmaceuticals (UK)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease: pain
Details: * On March 31, 2014, Evotec has announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Panion Ltd has been awarded a £ 2.4 m Technology Strategy Board Biomedical Catalyst Early Stage Round 2 grant to discover and develop compounds against a novel GPCR pain target. Evotec will be responsible for undertaking key drug discovery activities and will work closely with the Convergence team in identifying pre-clinical candidates over the next three years. Subsequently, and upon meeting certain pre-clinical milestones, Convergence and Evotec will jointly progress the assets further into the clinic or via partnering. Further financials remain undisclosed.
Financial terms:
Latest news:
